Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

@article{Krupitsky2011InjectableEN,
  title={Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial},
  author={E. Krupitsky and E. Nunes and W. Ling and A. Illeperuma and B. Silverman},
  journal={The Lancet},
  year={2011},
  volume={377},
  pages={1506-1513}
}
  • E. Krupitsky, E. Nunes, +2 authors B. Silverman
  • Published 2011
  • Medicine
  • The Lancet
  • BACKGROUND Opioid dependence is associated with low rates of treatment-seeking, poor adherence to treatment, frequent relapse, and major societal consequences. We aimed to assess the efficacy, safety, and patient-reported outcomes of an injectable, once monthly extended-release formulation of the opioid antagonist naltrexone (XR-NTX) for treatment of patients with opioid dependence after detoxification. METHODS We did a double-blind, placebo-controlled, randomised, 24-week trial of patients… CONTINUE READING
    332 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The aim of this project is to study brain functions of 20 heroin addicts (compared to brain functions of 20 healthy controls) just before and during a three month extended release… Expand
    ConditionsHeroin Dependence, Opioid-Related Disorders
    InterventionDrug
    Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX)
    • 35
    Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    • 14
    • PDF

    References

    SHOWING 1-10 OF 65 REFERENCES
    Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial.
    • 79
    • PDF
    Oral naltrexone maintenance treatment for opioid dependence.
    • 123